¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"toxic necrosis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pressure necrosis
    ¾Ð¹Ú±«»ç
  • progressive outer retinal necrosis
    ÁøÇ༺¿Ü¸Á¸·±«»ç
  • radiation necrosis
    ¹æ»ç¼±±«»ç
  • renal cortical necrosis
    ÄáÆÏ°ÑÁú±«»ç, ½ÅÀåÇÇÁú±«»ç
  • renal papillary necrosis
    ÄáÆÏÀ¯µÎ±«»ç, ½ÅÀåÀ¯µÎ±«»ç
  • subacute hepatic necrosis
    ¾Æ±Þ¼º°£±«»ç
  • subcutaneous fat necrosis
    ÇǺιØÁö¹æ±«»ç, ÇÇÇÏÁö¹æ±«»ç
  • zonal necrosis
    ±¸¿ª±«»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • subcutaneous fat necrosis
    ÇǺιØÁö¹æ±«»ç, ÇÇÇÏÁö¹æ±«»ç
  • traumatic fat necrosis
    ¿Ü»óÁö¹æ±«»ç
  • tubular necrosis
    ¿ä¼¼°ü±«»ç
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
  • toxic alopecia
    µ¶¼ºÅ»¸ðÁõ
  • toxic amaurosis
    Áßµ¶Èæ¾Ï½Ã
  • toxic amblyopia
    µ¶¼º¾à½Ã
  • toxic atrophy
    Áßµ¶À§Ãà
  • potentially toxic compound
    ÀáÀçµ¶¼º¹°Áú
  • toxic cardiopathy
    Áßµ¶½ÉÀ庴Áõ
  • toxic cataract
    Áßµ¶¹é³»Àå
  • toxic conjunctivitis
    µ¶¼º°á¸·¿°
  • toxic convulsion
    Áßµ¶°æ·Ã
  • toxic liver cirrhosis
    µ¶¼º°£°æÈ­(Áõ)
  • toxic deafness
    µ¶¼º³­Ã»
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • toxic chemical use
    µ¶¼ºÈ­Çй°ÁúÀÌ¿ë
  • toxic conjunctivitis
    Áßµ¶°á¸·¿°
  • toxic convulsion
    Áßµ¶¼º°æ·Ã(¡­ÌâÕý)
  • toxic convulsion
    Áßµ¶¼º°æ·Ã(¡­ÌâÕý).
  • toxic deafness
    Áßµ¶¼º³­Ã»
  • toxic delirium
    µ¶¼º¼¶¸Á(~àëØÍ).
  • toxic dementia
    Áßµ¶¼ºÄ¡¸Å(¡­öÂ?)
  • toxic diarrhea
    Áßµ¶¼º¼³»ç
  • toxic dose
    Áßµ¶(¿ë)·®(ñéÔ¸(éÄ)åÖ).
  • toxic dose
    µ¶¼º¿ë·®
  • toxic dyspepsia
    Áßµ¶¼º¼ÒÈ­ºÒ·®(ñéÔ¸àõá¼ûùÝÕåÐ)
  • toxic eczema
    Áßµ¶¼º½ÀÁø(¡­ã¥òÖ)
  • toxic edema
    Áßµ¶¼ººÎÁ¾
  • toxic effect
    Áßµ¶È¿°ú(¡­üùÍý).
  • toxic effect
    µ¶¼ºÈ¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ATN acute tubular necrosis; augmented transition network
AVN acute vasomotor nephropathy; atrioventricular nodal [conduction]; atrioventricular node; avascular n...
AVNFH avascular necrosis of the femoral head
BARN bilateral acute retinal necrosis
BCN basal cell nevus; bilateral cortical necrosis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TSST-1 Toxic Shock Syndrome Toxin-1
TSCA Toxic Substance Control Act
TA Toxic adenoma
TSST Toxic shock syndrome toxin
TSLS Toxic shock-like syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • pressure molding machine

    pressure necrosis

    ¾Ð¹Ú ±«»ç
  • pulp necrosis
    Ä¡¼ö ±«»ç
  • pulpal necrosis
    Ä¡¼ö ±«»ç
  • punched out necrosis
    õ°øµÈ ±«»ç
  • radiation necrosis
    ¹æ»ç¼± ±«»ç
  • thermal necrosis
    ¿­ ±«»ç
  • tissue necrosis
    Á¶Á÷ ±«»ç
    1. »ýü ³»ÀÇ Á¶Á÷ÀÌ ±¹ºÎÀûÀ¸·Î Á×´Â ÀÏ. 2. ±«»çÀÇ Á¾·ù¿¡´Â ÀÀ°í ±«»ç, ¾×È­ ±«»ç, ±«Àú ±«»ç°¡ ÀÖ´Ù.
  • traumatic fat necrosis
    ¿Ü»ó¼º Áö¹æ ±«»ç
  • traumatric fat necrosis
    ¿Ü»ó¼º Áö¹æ ±«»ç
  • tumor necrosis factor
    Á¾¾ç ±«»ç ÀÎÀÚ
    TNF. Á¾¾ç¿¡ °ü°èÇϰí ÀÖ´Â ¸é¿ª°èÀÇ ¼¼Æ÷ÀÎ Á¾¾ç ħÀ±¼º ¸²ÇÁ±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
toxic shock syndrome <syndrome> A blood-borne bacterial infection caused by the genus Staphylococcus. Usually effects menstruating females under the age of thirty and was associated in the past with the use of a particular type of tampon (no longer used).
Common symptoms include: fever, chills, vomiting, sore throat, headache and decreased urine output. Progression of disease can result in lowering of blood pressure (shock) and renal failure.
Treatment includes hospitalisation and intravenous antibiotics emergently.
(27 Sep 1997)
toxic substances A chemical or mixture of chemicals that presents a high risk of injury to human health or to the environment.
(05 Dec 1998)
toxic tetanus Tonic spasms caused by strychnine or other tetanic.
Synonym: toxic tetanus.
(05 Mar 2000)
toxic unit A unit formerly synonymous with minimal lethal dose but which, because of the instability of toxins, is now measured in terms of the quantity of standard antitoxin with which the toxin combines.
See: L doses, minimal lethal dose.
Synonym: toxin unit.
(05 Mar 2000)
epidermal necrolysis, toxic An exfoliative disease of skin seen primarily in adults and characterised by flaccid bullae and spreading erythema so that the skin has the appearance of being scalded. It results primarily from a toxic reaction to various drugs, but occasionally occurs as a result of infection, neoplastic conditions, or other exposure.
(12 Dec 1998)
acute tubular necrosis <nephrology> A kidney disorder that results in damage to the renal tubule cells leading to acute renal failure. Acute tubular necrosis can result from any condition which deprives the kidney of oxygen (ischaemia).
Acute tubular necrosis may occur as a complication of shock, trauma or sepsis. Conditions such as diabetes or liver disease can predispose people to the development of acute tubular necrosis. Certain medications (for example aminoglycosides, amphotericin B, cyclosporine) are known to cause acute tubular necrosis as a toxic side effect. Radiopaque contrast dyes, used in some radiologic procedures, may also result in acute tubular necrosis as a rare complication from contrast dye use.
Acronym: ATN
(13 Nov 1997)
aseptic necrosis <orthopaedics, pathology> Condition in which poor blood supply to an area of bone leads to bone death. Also called avascular necrosis and osteonecrosis.
(12 Dec 1998)
avascular necrosis <radiology> Aetiology (PLASTIC RAGS): P pancreatitis, L lupus, A alcohol, S steroids, T trauma, I idiopathic, infection, C caisson disease, collagen vascular disease, R radiation, rheumatoid arthritis, A amyloid, G Gaucher disease, S sickle cell disease findings: sclerosis, crescent sign, collapse (e.g., of femoral head) see also: staging
(12 Dec 1998)
avascular necrosis staging <radiology> Stage CT/X-ray bone scan I - cold/hot spot II sclerotic focus with osteopenic ring III crescent sign (subchondral lucency) IV articular collapse flattening of femoral head sensitivity 86% 78% specificity 79% 75% see also: avascular necrosis (AVN)
(12 Dec 1998)
bridging hepatic necrosis Area of liver necrosis which bridges adjacent portal areas and central veins; subsequent post-necrotic collapse and fibrosis is likely to result in cirrhosis.
(05 Mar 2000)
p60 tumour necrosis factor receptor-associated kinase <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor
Registry number: EC 2.7.10.-
Synonym: p60 tnf receptor-associated kinase, p60-trak
(26 Jun 1999)
papillary necrosis <radiology> Mnemonic: POST CARD, P pyelonephritis, O obstruction, S sickle cell disease, T TB, C cirrhosis (EtOH), A analgesics (phenacetin and aspirin), R renal vein thrombosis, D diabetes
(12 Dec 1998)
receptors, tumour necrosis factor Cell surface receptors that bind tumour necrosis factor and trigger changes which influence the behaviour of cells. The two recognised tumour necrosis factor receptors are designated alpha and beta receptors. Both receptors bind both alpha and beta tumour necrosis factors with high affinity, and both are members of the nerve growth factor receptor family.
(12 Dec 1998)
caseous necrosis Caseation necrosis, necrosis characteristic of certain inflammations (e.g., tuberculosis, histoplasmosis), which represents necrosis with loss of separate structures of the various cellular and histologic elements; affected tissue manifests the friable, crumbly consistency and dull, opaque quality observed in cheese.
Synonym: caseous degeneration.
(05 Mar 2000)
globus pallidus necrosis <radiology> Carbon monoxide poisoning, barbiturate intoxication, cyanide poisoning, hydrogen sulfide poisoning, hypoglycaemia, hypoxia, hypotension, Leigh disease, Wilson disease CT: bilateral, symmetric low density in globus pallidus Cf: methanol intoxication leading to putamenal haemorrhagic necrosis (changes seen more laterally)
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á